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Omitting duodenal biopsy in children
with suspected celiac disease and
extra-intestinal symptoms
Mauro Bozzola1* , Cristina Meazza1, Chiara Gertosio2, Sara Pagani1, Daniela Larizza1, Valeria Calcaterra1,
Ombretta Luinetti3, Giovanni Farello4, Carmine Tinelli5 and Lorenzo Iughetti6
Abstract
Background: The aim of our study is to evaluate if in children with highly positive serology and HLA-DQ2/
DQ8 (triple test, TT) and only extra-intestinal symptoms, it is possible to omit performing an intestinal biopsy
for celiac disease (CD) diagnosis, as suggested by the new European Society for Pediatric Gastroenterology,
Hepatology and Nutrition ESPGHAN guidelines.
Methods: In this retrospective study a total of 105 patients, suspected of having CD because of extra-intestinal
symptoms and showing serum tissue transglutaminase antibody (anti-tTG) and anti-endomysial antibody (EMA)
measurements and HLA genotyping, were considered for the final analysis (33 boys and 72 girls; age range
1.5–17.6 years).
Results: Histological findings confirmed diagnosis of CD in 97 (92.4%) patients. Forty-one patients (39%) showed
anti-tTG >10 times normal values, positive EMA and positive HLA-DQ2/DQ8 (positive TT). All of them had a diagnosis of
CD, therefore there were no false positive cases. Sixty-four patients were negative for the TT. In eight cases, CD was ruled
out and these were considered true negative cases. In the remaining 56 negative TT patients, intestinal biopsy confirmed
CD diagnosis and they were considered false negatives. Based on these results, specificity for the TT was 100%
and sensitivity was 42.3%.
Conclusions: On the basis of the present study, diagnosis of CD can be reliably performed without a duodenal
biopsy in children with only extra-intestinal symptoms.
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Background
According to the first guidelines established by the
European Society for Pediatric Gastroenterology,
Hepatology and Nutrition (ESPGHAN) in 1969 [1], celiac
disease (CD) diagnosis depended on gluten-dependent
symptoms and characteristic histological changes (villous
atrophy, crypt hyperplasia, increase of intraepithelial lym-
phocytes) found in the duodenal biopsy.
Anti-endomysial antibodies (EMA) were discovered
in the 1980s [2] and tissue transglutaminase antibodies
(anti-tTG) were identified as a celiac autoantigen in the
late 1990s [3]. Furthermore, in the last few years both
the sensitivity and specificity of the serological tests
have increased to nearly perfect values and some stu-
dies have been published suggesting that these tests
alone may be sufficient to confirm the diagnosis of CD
[4, 5]. In addition, a strong association of CD with the
genetic markers human leukocyte antigen (HLA)-DQ2
and/or HLA-DQ8 has been established [6]. Therefore,
considering these new scientific and technical develop-
ments and using an evidence-based approach, a working
group within ESPGHAN formulated guidelines for CD
diagnosis offering the option of not performing the intes-
tinal biopsy in children and adolescents [7]. The require-
ments for omitting intestinal biopsy are gastrointestinal
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symptoms and signs suggestive of CD, anti-tTG antibody
levels of more than 10 times the upper normal limit, posi-
tive confirmation of EMA and the presence of at risk
HLA-DQ2 or HLA-DQ8. If all requirements are fulfilled,
a gluten-free diet (GFD) is started and the patient is
followed for improvement in symptoms and decrease of
autoantibodies.
In the last few years, many studies have obviously been
aimed at validating the indications of the ESPGHAN
guidelines. Some of them confirmed that performing a
duodenal biopsy can be omitted in a selected population
of children and adolescents [8–10], while some others
claimed that prudence is necessary in making a diagnosis
of CD without duodenal biopsy [11, 12]. In fact, some
authors suggest that symptoms are an essential part of
CD diagnosis, although serological tests are highly sensi-
tive and specific for CD [10]. A recent description of a
child with a potential CD underlines the fact that strictly
following the ESPGHAN guidelines could avoid intes-
tinal biopsy but would consider a patient who is perhaps
just potentially affected as celiac [13]. It is therefore im-
portant to repeat the CD serology before starting a GFD
without a biopsy.
It is well known that CD can manifest with only
extra-intestinal symptoms, the so-called non-classical
CD, such as iron and folic acid deficiency with or with-
out anaemia, dermatitis herpetiformis, delayed puberty,
short stature, enamel defects, recurrent aphthous sto-
matitis, etc. [14].
The aim of our retrospective study was to evaluate
whether serological markers combined with determi-
nation of HLA-DQ2/DQ8 genotype could replace the
intestinal biopsy in children suspected of having CD but
with only extra-intestinal symptoms.
Methods
We conducted a retrospective study involving 268 children
and adolescents suspected of having CD due to extra-
intestinal symptoms (Table 1). They had been referred
to various highly specialised Italian Endocrinological
Centres: Unità di Pediatria Auxologia, Fondazione
IRCCS Policlinico San Matteo, Pavia; Dipartimento di
Pediatria, Università di Modena and Reggio Emilia,
Modena and Ospedale de L’Aquila, L’Aquila. All research
was performed according to the Ethical Standards invol-
ving human participants. The study was approved by the
Ethics Committee “Comitato Etico Area di Pavia” of the
Fondazione IRCCS Policlinico San Matteo. All partici-
pants provided parental written informed consent. Firstly,
children were checked for anti-tTG and/or EMA. Then,
as a consequence of positive serology, they underwent
intestinal biopsy and in most cases HLA-DQ2/DQ8 geno-
typing was performed. The histology considered the
standard criterion for CD diagnosis according to the 2012
ESPGHAN guidelines [7].
According to the aim of our study and based on the
ESPGHAN guidelines for the diagnosis of CD in chil-
dren [7], we decided to consider anti-tTG, EMA and
HLA-DQ2/DQ8 as a triple test (TT) for the diagnostic
approach. We defined a TT as positive if anti-tTG was
>10 times normal values, together with positive EMA
and a positive HLA-DQ2 and/or DQ8. All three parame-
ters had only been measured in 105 patients and these
were thus considered for the final analysis. Thirty-three
(31.4%) were boys and 72 (68.6%) were girls. The age
range was 1.5–17.6 years, mean (SD) being 7.6 (4.2)
years; only seven (6.7%) were younger than 2 years.
The other 163 children showed positive anti-tTG
(although not always >10 times normal values) and/or
positive EMA. Only in 31 out of 163 children had HLA
genotyping been performed and showed a positive HLA-
DQ2 and/or DQ8. One hundred fifty six children were
diagnosed as celiac according to the result of intestinal
biopsy, while the remaining seven children did not show
histological findings suggestive of CD.
EMA were detected by indirect immunofluorescence on
sections from the distal portion of monkey oesophagus, as
an antigenic substrate, using a commercially available
assay kit (GmbH Labordiagnostik, München). Serum anti-
tTG IgA and IgG levels were determined by a commer-
cially available enzyme-immunosorbent assay (ELISA) kit
(Eu-tTG IgA and IgG, Eurospital, Trieste, Italy).
To evaluate the presence of celiac-susceptible DQ he-
terodimers, the patients were typed for HLA class II
polymorphisms by PCR-SSP at high resolution level.
DNA was extracted by a salting out procedure [15].
Polymorphism within the exons 2 of HLA-DQA1 and
DQB1 genes was defined using a polymerase chain reac-
tion with sequence specific primers (PCR-SSP) [16].
Statistical analysis
Quantitative variables are described as mean and stan-
dard deviation (SD); qualitative ones are described as
counts and percentages. Ninety five percent Confidence
Intervals (CI) were calculated for sensitivity, specificity,
positive and negative predictive value. Comparisons be-
tween the different groups were evaluated with Fisher’s
Table 1 Extra-intestinal symptoms of the enrolled patients
suspected of CD
• Failure to thrive
• Dhort stature
• Delayed puberty
• Weight loss
• Iron deficiency anaemia
• Enamel defects
• Dermatitis herpetiformis
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exact test. The data analysis was performed with the
STATA statistical package (release 14.0, 2015, Stata
Corporation, College Station, Texas, USA).
Results
Diagnosis of CD was done in 97 (92.4%) patients by the
confirmation with histological findings on intestinal
biopsy. After the diagnosis of CD was made, GFD was
recommended to all patients.
Only 41 patients (39%) were positive for the triple test
(Fig. 1). All of them had either Marsh 2 or Marsh 3
histological lesions and a definitive diagnosis of CD was
made. These were true positive cases for the TT. Thus,
the positive predicted value (PPV) of the TT was 100%
(95% CI: 96%–100%) (Table 2). There were Therefore no
false positive cases.
Sixty-four patients were negative for the triple test. In
eight cases, CD was ruled out by duodenal biopsy and
these were considered true negative cases (Fig. 1, Table 2).
Five of eight had normal histology, two had Marsh 1 his-
tological lesions and were classified as potential CD and
one had a diagnosis of duodenopathy. All subjects with
negative TT were HLA-DQ2/DQ8 positive but had either
positive anti-tTG or EMA. Only one girl showed both
negative EMA and IgA-tTG. In the remaining 56 patients
with negative TT, intestinal biopsy confirmed the diagno-
sis of CD and they were considered false negatives. Based
on these results, specificity for the TT was 100% (95% CI:
96%–100%) and sensitivity was 42.3%, (95% CI: 33.2%–
52.9%), while negative predictive value (NPP) was 12.5%
(95% CI: 6.7%-20.2) (Table 2).
In the CD group, 44.3% of patients showed anti-tTG
levels >10 times normal values, 15.4% 6–10 times nor-
mal values, 35.1% 1–5 times normal values and 5.2%
negative values (Fig. 2). On the contrary, the percentages
of patients according to anti-tTG values were different
in the no-CD group: no patients showed anti-tTG levels
>10 times normal values, 12.5% 6–10 times normal
values, 62.5% 1–5 times normal values and 25% negative
values (Fig. 2) (p < 0.001).
Discussion
Our retrospective study tested the performance of the
ESPGHAN guidelines for the non-biopsy CD diagnosis
in children with only extra-intestinal symptoms.
For decades, the diagnosis of CD has been based on
the histological analysis of duodenal biopsy samples,
preferably taken during an upper endoscopy [17]. How-
ever, growing evidence indicates the pitfalls of histology
due to the number, site, size and orientation of biopsy
samples [18]. Serological testing of the so-called celiac
antibodies has become increasingly important for the
diagnosis of CD. In particular, the discovery of the en-
zyme tTG as the major autoantigen involved in CD
pathogenesis led to the development of routine assays
for anti-tTG determination [19]. Furthermore, HLA
genotyping results, with a high diagnostic sensitivity but
a low specificity, have a primary role in excluding CD
[20]. Taking into account all these factors, there is a
growing interest in the debate over the omission of per-
forming duodenal biopsies according to the ESPGHAN
guidelines for the diagnosis of CD in children and ado-
lescents in the presence of symptoms and high levels of
anti-tTG [5]. More recently, the British Society of
Paediatric Gastroenterology, Hepatology and Nutrition
Fig. 1 Results of the triple test in our population. CD = celiac disease
Table 2 Efficiency of the triple test (TT) in patients with extra-
intestinal symptoms, suspected of having CD
Positive biopsy
n = 97
Negative biopsy
n = 8
Positive TT
(n = 41)
True positive 41 False positive 0 Positive predictive
value 100%
Negative TT
(n = 64)
False negative 56 True negative 8 Negative predictive
value 12.5%
Sensitivity
42.3%
Specificity
100%
Fig. 2 Distribution of patients by anti-tTG levels. Negative anti-tTG
(white bar); 1–5 times normal values (grey bar); 6–10 times normal
values (black bar); >10 times normal values (shaded bar)
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(BSPGHAN) also reviewed its diagnostic guidelines for
CD, reaching similar conclusions [21]. A very recent
prospective study showed that diagnosis of CD can be
reliably performed without a duodenal biopsy in ap-
proximately 11% of cases, selected applying the ESP-
GHAN/BSPGHAN guidelines in a restricted way,
considering as symptomatic only those cases with diar-
rhoea, weight loss, failure to thrive and iron deficiency
anaemia [22]. However, some studies suggest prudence
in omitting performance of a duodenal biopsy in these
children. Guandalini and colleagues expressed concerns
about the skipping of duodenal biopsy to confirm the
diagnosis of CD. They demonstrated that if the diagno-
sis of CD is made without the endoscopy, any unex-
pected disorders of the upper gastrointestinal tract will
be missed. They therefore suggest that it is mandatory
to closely follow up patients on a GFD and evaluate
those with unresolved symptoms [11].
In our study, only 39% of patients suspected for CD
showed positivity for the TT and would have been eli-
gible for diagnosis without intestinal biopsy, according
to the ESPGHAN guidelines. We found that all the TT
positive patients were celiac and the specificity for this
test was 100%, confirming that this test is reliable and
that it is possible to not perform a duodenal biopsy also
in patients with only extra-intestinal symptoms. How-
ever, a prudent approach is suggested when a diagnosis
of CD is made without intestinal biopsy, since the anti-
tTG antibody titre could sometimes be elevated due to a
gastrointestinal infection and not to CD, as shown in the
case reported by Schirru et al. [12]. More recently, an-
other case report described a two-year-five-month-old
child with familiarity for CD, elevated anti-tTG anti-
bodies and positive EMA who was negative to biopsy
and classified as potential CD [13]. Therefore, it is im-
portant to closely follow up this kind of patient for some
weeks and, if necessary, repeat the serology before star-
ting a GFD without a biopsy. Otherwise, a patient who is
only potentially affected or has elevated anti-tTG levels
due to other causes would be considered as celiac.
On the contrary, we found that the sensitivity of TT
was only 42.3%, suggesting that biopsy is necessary for
confirming the diagnosis in patients with negative TT,
even if the anti-tTG titre is high and they show HLA-
DQ2 or -DQ8. In fact, 56 out of 64 patients suspected of
having CD but with negative TT were celiac subjects
and only eight did not show the disease. Furthermore,
three of the latter showed histological lesions due to dif-
ferent duodenopathies.
Triple test should therefore not be used as a screening
test for CD, because of its low sensitivity, much lower
than anti-tTG measurement sensitivity. Therefore, when
clinicians are faced with patients in whom CD symptoms
are only extra-intestinal and serological markers are not
so elevated, intestinal biopsy is mandatory in order to
avoid the risk of these patients remaining undiagnosed
and being exposed to the risk of long-term complica-
tions, such as osteoporosis, infertility and cancer, espe-
cially lymphomas [23]. Recently, our group reported the
development of positive serology for CD in a child with-
out gastrointestinal symptoms and only growth retar-
dation, who had previously been investigated for CD and
proved negative [24], further suggesting that a close
follow-up of patients in whom a CD diagnosis is difficult
is very important.
Conclusion
On the basis of the present study, diagnosis of CD can
be reliably performed without a duodenal biopsy also in
children with only extra-intestinal symptoms and the
characteristics suggested by the ESPGHAN guidelines.
However, these patients represent only a small part of all
patients with only extra-intestinal symptoms investigated
for CD. In the other group of subjects, duodenal biopsy
remains mandatory to confirm CD diagnosis.
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